Regentis Biomaterials Ltd.
RGNT NYSE· Orthopedic, Prosthetic & Surgical Appliances & Supplies
Last close · Oct 26, 2026
$1.26
KIRA · Stoqly’s AI analyst, in plain words
- Regentis Biomaterials Ltd. lost $13.6M in fiscal 2025.
- Regentis Biomaterials Ltd. has $6.2M more cash than debt.
Market cap
$0.7M
P/E
—
Revenue
—
Net income
−$13.6M
Free cash flow
—
Operating margin
—
Regentis Biomaterials Ltd. in 30 seconds · fiscal 2025
Does it make a profit?
−$13.6M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Regentis Biomaterials Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Feb 24, 2026
- Legal name
- REGENTIS BIOMATERIALS LTD.
- CIK
- 0001912966
Regentis Biomaterials Ltd. · RGNT
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$4.1M | $4.8M | −$13.6M |
| Diluted EPS | −$24.09 | $1.72 | −$24.16 |
| Cash | |||
| Cash from operations | −$1.2M | −$0.6M | −$1.4M |
| Share count change | — | 1,494.2% | −79.5% |
| Debt and strength | |||
| Cash and short-term investments | — | — | $7.4M |
| Debt incl. finance leases | $0.2M | $0.6M | $1.2M |
| Shareholders' equity | −$45.9M | −$41.1M | $4.7M |
| Interest coverage | — | 93.2x | −88.2x |
| Returns and quality | |||
| Return on tangible equity | — | — | −287.7% |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Regentis Biomaterials Ltd. · RGNT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.26 a share, the company is worth $0.7M.
Source: SEC EDGAR XBRL filings (CIK 0001912966). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.